Related Experiment Video
Updated: Apr 15, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy
Sebastian Huss1, Sandra Elges, Marcel Trautmann
1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Building D17, Albert-Schweitzer-Campus 1, Münster 48149, Germany.
Abstract:
Gastrointestinal stromal tumors (GIST) are driven mostly by oncogenic KIT or PDGFRA mutations. However, in 10-15% of all GIST, no such activating mutations can be found and these tumors are classified as 'wild-type GIST' (KIT/PDGFRA wt-GIST). Subgroups of KIT/PDGFRA wt-GIST are driven by other sporadic mutations involving the RAS/RAF/MAP-kinase pathway, such as BRAF or KRAS mutations. Furthermore, KIT/PDGFRA wt-GIST are observed in the context of hereditary syndromes, such as neurofibromatosis Type 1, in which the lack of neurofibromin 1 also leads to the activation of the RAS/RAF/MAP-kinase pathway. Finally, the deficiency succinate dehydrogenase seems to play a major role in KIT/PDGFRA wt-GIST. In conclusion, KIT/PDGFRA wt-GIST belong to different subgroups defined by diverse underlying genetic alterations leading to different biological phenotypes. The vast majority of KIT/PDGFRA wt-GIST will not respond to imatinib. Further research to unravel the pathogenesis of KIT/PDGFRA wt-GIST is prerequisite to the development of effective treatment strategies.
Insights
Wild-type gastrointestinal stromal tumors (GIST) lack KIT/PDGFRA mutations and are driven by diverse genetic alterations. These tumors often do not respond to imatinib, necessitating further research for effective treatments.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastrointestinal stromal tumors (GIST) are primarily driven by KIT or PDGFRA mutations.
- A subset of GIST, termed 'wild-type GIST' (KIT/PDGFRA wt-GIST), lacks these common mutations.
- Understanding the molecular drivers of KIT/PDGFRA wt-GIST is crucial for therapeutic development.
Purpose of the Study:
- To review the diverse genetic alterations underlying KIT/PDGFRA wt-GIST.
- To explore the biological phenotypes associated with different genetic drivers.
- To highlight the implications for treatment strategies, particularly imatinib response.
Main Methods:
- Literature review and synthesis of existing research on GIST genetics.
- Analysis of molecular pathways involved in KIT/PDGFRA wt-GIST pathogenesis.
- Review of clinical data regarding treatment responses in different GIST subtypes.
Main Results:
- KIT/PDGFRA wt-GIST encompass distinct subgroups driven by mutations in the RAS/RAF/MAP-kinase pathway (e.g., BRAF, KRAS).
- Hereditary syndromes like neurofibromatosis Type 1 contribute to wt-GIST through neurofibromin 1 deficiency and pathway activation.
- Succinate dehydrogenase deficiency is implicated in a significant proportion of wt-GIST.
- The majority of KIT/PDGFRA wt-GIST exhibit resistance to imatinib therapy.
Conclusions:
- KIT/PDGFRA wt-GIST represent a heterogeneous group with varied genetic underpinnings and biological behaviors.
- Current treatments like imatinib are largely ineffective against most wt-GIST.
- Further research into the pathogenesis of wt-GIST is essential for developing targeted and effective therapeutic strategies.
More Related Videos
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024